FDA: Novo Nordisk’s Obesity Pill Ad Is Misleading

The Food and Drug Administration has warned Novo Nordisk that a television advertisement promoting its newly launched Wegovy pill for obesity contains “false or misleading” claims, saying the spot misbrands the drug and violates federal law, CNBC reported Monday.[#item_full_content]

Related articles

You may also be interested in

Headline

Never Miss A Story

Get our Weekly recap with the latest news, articles and resources.
Cookie policy

We use our own and third party cookies to allow us to understand how the site is used and to support our marketing campaigns.